In atopic dermatitis models, quercetin shows potential as a targeted therapy (Hou et al., 2019), while coptisine alleviates inflammation by suppressing the TXNIP/NLRP3 inflammasome (Li et al., 2024). Here, TXNIP is linked to atopic eczema.